OBJECTIVES: Statins reduce cardiovascular events by cholesterol-lowering as well as nonlipid-related actions. Thrombin activatable fibrinolysis inhibitor (TAFI) is a recently identified independent risk factor of thrombosis. Endothelial dysfunction is also a strong predictor of cardiovascular events. The aim of this study was to assess the effects of simvastatin treatment on circulating TAFI concentrations and endothelial function in patients with hypercholesterolemia. METHODS: Thirty-five patients (19 female, mean age 48 +/- 7 years) with hyperlipidemia were recruited into the study. Simvastatin was administered, 40 mg daily, for eight weeks to all subjects. Study subjects did not receive any medication except for lipid-lowering therapy during the follow-up period. Endothelial function was evaluated by flow-mediated dilation (FMD) from the brachial artery of the patients. Plasma lipid parameters, TAFI levels and endothelial function were measured before and after simvastatin treatment. RESULTS: Treatment with simvastatin showed a significant decrement in plasma total cholesterol, LDL cholesterol and triglyceride levels (p<0.05). Plasma TAFI levels were also significantly decreased after simvastatin treatment [median 17.0 (range 0.4-93.7) mcg/mL versus median 6.9 (range 0.8-63.0) mcg/mL, p<0.001]. Mean FMD was measured 7.7 +/- 2.5% at baseline and significantly improved after treatment (13.0 +/- 1.4%) (p=0.001). CONCLUSION: Our findings of decreased TAFI levels may reflect the beneficial effect of simvastatin treatment on fibrinolysis, and improved endothelial function may suggest the improved future cardiovascular events in hyperlipidemic patients.
OBJECTIVES: Statins reduce cardiovascular events by cholesterol-lowering as well as nonlipid-related actions. Thrombin activatable fibrinolysis inhibitor (TAFI) is a recently identified independent risk factor of thrombosis. Endothelial dysfunction is also a strong predictor of cardiovascular events. The aim of this study was to assess the effects of simvastatin treatment on circulating TAFI concentrations and endothelial function in patients with hypercholesterolemia. METHODS: Thirty-five patients (19 female, mean age 48 +/- 7 years) with hyperlipidemia were recruited into the study. Simvastatin was administered, 40 mg daily, for eight weeks to all subjects. Study subjects did not receive any medication except for lipid-lowering therapy during the follow-up period. Endothelial function was evaluated by flow-mediated dilation (FMD) from the brachial artery of the patients. Plasma lipid parameters, TAFI levels and endothelial function were measured before and after simvastatin treatment. RESULTS: Treatment with simvastatin showed a significant decrement in plasma total cholesterol, LDL cholesterol and triglyceride levels (p<0.05). Plasma TAFI levels were also significantly decreased after simvastatin treatment [median 17.0 (range 0.4-93.7) mcg/mL versus median 6.9 (range 0.8-63.0) mcg/mL, p<0.001]. Mean FMD was measured 7.7 +/- 2.5% at baseline and significantly improved after treatment (13.0 +/- 1.4%) (p=0.001). CONCLUSION: Our findings of decreased TAFI levels may reflect the beneficial effect of simvastatin treatment on fibrinolysis, and improved endothelial function may suggest the improved future cardiovascular events in hyperlipidemic patients.
Authors: T Tsunekawa; T Hayashi; H Kano; D Sumi; H Matsui-Hirai; N K Thakur; K Egashira; A Iguchi Journal: Circulation Date: 2001-07-24 Impact factor: 29.690
Authors: Jared M Pisapia; Xiangsheng Xu; Jane Kelly; Jamie Yeung; Geneive Carrion; Huaiyu Tong; Sudha Meghan; Omar M El-Falaky; M Sean Grady; Douglas H Smith; Sergei Zaitsev; Vladimir R Muzykantov; Michael F Stiefel; Sherman C Stein Journal: Exp Neurol Date: 2011-11-04 Impact factor: 5.330
Authors: N L Smith; L B Harrington; M Blondon; K L Wiggins; J S Floyd; C M Sitlani; B McKnight; E B Larson; F R Rosendaal; S R Heckbert; B M Psaty Journal: J Thromb Haemost Date: 2016-06-20 Impact factor: 5.824
Authors: Zhi-Jiang Zhang; Oscar C Marroquin; Joel L Weissfeld; Roslyn A Stone; Suresh R Mulukutla; David O Williams; Faith Selzer; Kevin E Kip Journal: Eur J Cardiovasc Prev Rehabil Date: 2009-08
Authors: Christine Y Ivashchenko; Benjamin T Bradley; Zhaohui Ao; James Leiper; Patrick Vallance; Douglas G Johns Journal: Am J Physiol Heart Circ Physiol Date: 2009-11-13 Impact factor: 4.733
Authors: Kevin C Maki; Tia M Rains; Arianne L Schild; Mary R Dicklin; Keigan M Park; Andrea L Lawless; Kathleen M Kelley Journal: Vasc Health Risk Manag Date: 2013-07-23
Authors: Suzanne Schol-Gelok; Moniek P M de Maat; Joseph S Biedermann; Teun van Gelder; Frank W G Leebeek; Willem M Lijfering; Felix J M van der Meer; Dingeman C Rijken; Jorie Versmissen; Marieke J H A Kruip Journal: Br J Haematol Date: 2020-04-16 Impact factor: 6.998